No evidence for hypogammaglobulinemia in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with ravulizumab.

Ferras AlashkarScott RottinghausColin VanceDörte Herich-TerhürneUlrich DührsenRoland AssertAlexander Röth

Published in: PloS one (2020)

In ravulizumab-treated PNH patients, IgG and IgG subclass levels which are regulated by the FcRn remained unaffected. Therefore, no treatment associated hypogammaglobulinemia is to be feared under chronic ravulizumab therapy.

Keyphrases

newly diagnosed
end stage renal disease
chronic kidney disease
blood pressure
atrial fibrillation
peritoneal dialysis
obstructive sleep apnea
stem cells
replacement therapy
drug induced